In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term 'migrastatics' for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

Ayurveda Molecular Modeling Hyderabad Telangana India

Central European Institute of Technology Brno University of Technology Brno Czech Republic

Charles University Department of Internal Medicine 3rd Faculty of Medicine Prague Czech Republic

Department of Cell Biology Charles University Viničná 7 Prague Czech Republic; Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University Průmyslová 595 25242 Vestec u Prahy Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Medbase Chapel Hill NC USA

Tumor Plasticity Laboratory Randall Division of Cell and Molecular Biophysics Guy's Campus King's College London London UK

Zobrazit více v PubMed

Prick J. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. Exp. Hematol. 2014;42:841–851. PubMed

Nowell P.C. The clonal evolution of tumor cell populations. Science. 1976;194:23–28. PubMed

Brenner M.K. Hematological malignancies. FASEB J. 1997;11:640–648. PubMed

Fernandes M. Translation in solid cancer: are size-based response criteria an anachronism? Clin. Transl. Oncol. 2015;17:1–10. PubMed

Sleeman J., Steeg P.S. Cancer metastasis as a therapeutic target. Eur. J. Cancer. 2010;46:1177–1180. PubMed PMC

Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. PubMed

Lazebnik Y. What are the hallmarks of cancer? Nat. Rev. Cancer. 2010;10:232–233. PubMed

Rösel D. Drugs for solid cancer: the productivity crisis prompts a rethink. Onco. Targets. Ther. 2013;6:767–777. PubMed PMC

Seymour L. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–e152. PubMed PMC

Cragg G.M. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 2009;109:3012–3043. PubMed

Block K.I. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol. 2015;35(Suppl):S276–S304. PubMed PMC

Bronsert P. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer–host interface. J Pathol. 2014;234:410–422. PubMed

Friedl P. Classifying collective cancer cell invasion. Nat. Cell Biol. 2012;14:777–783. PubMed

Panková K. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell. Mol. Life Sci. 2010;67:63–71. PubMed PMC

Clark A.G., Vignjevic D.M. Modes of cancer cell invasion and the role of the microenvironment. Curr. Opin. Cell Biol. 2015;36:13–22. PubMed

Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer. 2003;3:362–374. PubMed

Wolf K. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003;160:267–277. PubMed PMC

Brábek J. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun. Signal. 2010;8:22. PubMed PMC

Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003;5:711–719. PubMed

Sanz-Moreno V. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008;135:510–523. PubMed

Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2016;41:49–61. PubMed PMC

Gillis N.K., McLeod H.L. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist. Updat. 2016;28:28–42. PubMed PMC

Mitchison T.J., Cramer L.P. Actin-based cell motility and cell locomotion. Cell. 1996;84:371–379. PubMed

Fife C.M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br. J. Pharmacol. 2014;171:5507–5523. PubMed PMC

Olson M.F., Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis. 2009;26:273–287. PubMed

Tolde O. The structure of invadopodia in a complex 3D environment. Eur. J. Cell Biol. 2010;89:674–680. PubMed

Aratyn-Schaus Y. Dynamic and structural signatures of lamellar actomyosin force generation. Mol. Biol. Cell. 2011;22:1330–1339. PubMed PMC

Salbreux G. Actin cortex mechanics and cellular morphogenesis. Trends Cell Biol. 2012;22:536–545. PubMed

Levayer R., Lecuit T. Biomechanical regulation of contractility: spatial control and dynamics. Trends Cell Biol. 2012;22:61–81. PubMed

Amano M. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) J. Biol. Chem. 1996;271:20246–20249. PubMed

Kimura K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) Science. 1996;273:245–248. PubMed

Wilkinson S. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 2005;7:255–261. PubMed

Yamaguchi H., Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim. Biophys. Acta. 2007;1773:642–652. PubMed PMC

Gross S.R. Actin binding proteins: their ups and downs in metastatic life. Cell Adh. Migr. 2013;7:199–213. PubMed PMC

Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010;9:790–803. PubMed PMC

Trendowski M. Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochim. Biophys. Acta. 2014;1846:599–616. PubMed

Fenteany G., Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr. Top. Med. Chem. 2003;3:593–616. PubMed

Allingham J.S. Actin-targeting natural products: structures, properties and mechanisms of action. Cell. Mol. Life Sci. 2006;63:2119–2134. PubMed PMC

Hayot C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol. Appl. Pharmacol. 2006;211:30–40. PubMed

Van Goietsenoven G. In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med. 2011;77:711–717. PubMed

Murray D. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br. J. Cancer. 2008;99:1322–1329. PubMed PMC

Sun W. Mechanistic adaptability of cancer cells strongly affects anti-migratory drug efficacy. J. R. Soc. Interface. 2014;11:20140638. PubMed PMC

Huang F.-Y. Cytochalasin D promotes pulmonary metastasis of B16 melanoma through expression of tissue factor. Oncol. Rep. 2013;30:478–484. PubMed

Singh J., Hood R.D. Effects of protein deficiency on the teratogenicity of cytochalasins in mice. Teratology. 1987;35:87–93. PubMed

Hagmar B., Ryd W. Tumor cell locomotion ​ – a factor in metastasis formation? Influence of cytochalasin B on a tumor dissemination pattern. Int. J. Cancer. 1977;19:576–580. PubMed

Hart I.R. Effect of cytoskeleton-disrupting agents on the metastatic behavior of melanoma cells. J. Natl. Cancer Inst. 1980;64:891–900. PubMed

Bousquet P.F. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res. 1990;50:1431–1439. PubMed

Bogyo D. Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2. Cancer Immunol. Immunother. 1991;32:400–405. PubMed PMC

Tannert R. Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin. J. Am. Chem. Soc. 2010;132:3063–3077. PubMed

Freitas V.M. The geodiamolide H, derived from Brazilian sponge Geodia corticostylifera, regulates actin cytoskeleton, migration and invasion of breast cancer cells cultured in three-dimensional environment. J. Cell. Physiol. 2008;216:583–594. PubMed

Yarmola E.G. Actin-latrunculin A structure and function. Differential modulation of actin-binding protein function by latrunculin A. J. Biol Chem. 2000;275:28120–28127. PubMed

Ahmed S.A. Latrunculin with a highly oxidized thiazolidinone ring: structure assignment and actin docking. Org. Lett. 2007;9:4773–4776. PubMed PMC

Nummela P. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res. 2006;66:701–712. PubMed

Tolde O. Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP. Int. J. Oncol. 2010;36:833–839. PubMed

Amornphimoltham P. Rab25 regulates invasion and metastasis in head and neck cancer. Clin. Cancer Res. 2013;19:1375–1388. PubMed PMC

Sayed K.A. El. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J. Nat. Prod. 2008;71:396–402. PubMed PMC

Khanfar M.A. Semisynthetic latrunculin derivatives as inhibitors of metastatic breast cancer: biological evaluations, preliminary structure-activity relationship and molecular modeling studies. ChemMedChem. 2010;5:274–285. PubMed PMC

Konishi H. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res. 2009;29:2091–2097. PubMed

Bubb M.R. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J. Biol. Chem. 1994;269:14869–14871. PubMed

Takeuchi H. Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma. Cancer Chemother. Pharmacol. 1998;42:491–496. PubMed

Kunze B. Chondramides A approximately D, new antifungal and cytostatic depsipeptides from Chondromyces crocatus (Myxobacteria) Production, physico-chemical and biological properties. J. Antibiot. (Tokyo) 1995;48:1262–1266. PubMed

Menhofer M.H. The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. PLoS One. 2014;9:e112542. PubMed PMC

Sorensen P.M. The natural product cucurbitacin E inhibits depolymerization of actin filaments. ACS Chem. Biol. 2012;7:1502–1508. PubMed PMC

Zhang T. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res. Treat. 2012;135:445–458. PubMed

Rodriguez-Hernandez I. Rho, ROCK and actomyosin contractility in metastasis as drug targets. F1000Research. 2016;5 F1000 Faculty Rev-783. PubMed PMC

Kosla J. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. Cell Commun. Signal. 2013;11:51. PubMed PMC

Sanz-Moreno V. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 2011;20:229–245. PubMed

Stehn J.R. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res. 2013;73:5169–5182. PubMed

Duxbury M.S. Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: a novel myosin II inhibitor. Biochem. Biophys. Res. Commun. 2004;313:992–997. PubMed

Arozarena I. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011;19:45–57. PubMed

Kim J.H., Adelstein R.S. LPA(1)-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J. Cell. Physiol. 2011;226:2881–2893. PubMed PMC

Derycke L. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int. J. Dev. Biol. 2011;55:835–840. PubMed

Seifert S., Sontheimer H. Bradykinin enhances invasion of malignant glioma into the brain parenchyma by inducing cells to undergo amoeboid migration. J. Physiol. 2014;592:5109–5127. PubMed PMC

Totsukawa G. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 2000;150:797–806. PubMed PMC

Kaneko K. Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines. Pancreas. 2002;24:34–41. PubMed

Tohtong R. Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain. Prostate Cancer Prostatic Dis. 2003;6:212–216. PubMed

Gu L.-Z. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur. J. Cancer. 2006;42:948–957. PubMed

Nakagawa O. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193. PubMed

Ying H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther. 2006;5:2158–2164. PubMed

Ogata S. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int. J. Gynecol. Cancer. 2009;19:1473–1480. PubMed

Zhu F. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med. Oncol. 2011;28:565–571. PubMed

Deng L. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol. Ther. 2010;9:875–884. PubMed

Yang X. Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. Can. J. Physiol. Pharmacol. 2010;88:874–879. PubMed

Yang X. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed. Pharmacother. 2012;66:221–227. PubMed

Hu K. Suppression of hepatocellular carcinoma invasion and metastasis by Rho-kinase inhibitor Fasudil through inhibition of BTBD7-ROCK2 signaling pathway. Zhong Nan Da Xue Xue Bao. Yi Xue Ban. 2014;39:1221–1227. PubMed

Moreira Carboni Sde S. HA-1077 inhibits cell migration/invasion of oral squamous cell carcinoma. Anticancer Drugs. 2015;26:923–930. PubMed

Nakashima S. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol. Med. Chir. (Tokyo) 1998;38:801–805. PubMed

Uehata M. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994. PubMed

Itoh K. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999;5:221–225. PubMed

Somlyo A.V. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 2000;269:652–659. PubMed

Takamura M. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology. 2001;33:577–581. PubMed

Saurin J.-C. Bombesin stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-dependent manner. Cancer Res. 2002;62:4829–4835. PubMed

Yoshioka K. A role for LIM kinase in cancer invasion. Proc. Natl. Acad. Sci. U. S. A. 2003;100:7247–7252. PubMed PMC

Wang D.-S. Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J. Gastroenterol. 2004;10:299–302. PubMed PMC

Zhong W.-B. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr. Relat. Cancer. 2005;12:615–629. PubMed

Lawler K. Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am. J. Physiol. Cell Physiol. 2006;291:C668–C677. PubMed

Hakuma N. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res. 2005;65:10776–10782. PubMed

Xue F. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol. Res. 2008;38:810–817. PubMed

Routhier A. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol. Rep. 2010;23:861–867. PubMed

Nakashima M., Lazo J.S. Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics. J. Pharmacol. Exp. Ther. 2010;334:627–633. PubMed PMC

Wang L. Autocrine motility factor receptor signaling pathway promotes cell invasion via activation of ROCK-2 in esophageal squamous cell cancer cells. Cancer Invest. 2010;28:993–1003. PubMed

Jeong K.J. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene. 2012;31:4279–4289. PubMed

Zhao M. Expression of serum response factor in gastric carcinoma and its molecular mechanisms involved in the regulation of the invasion and migration of SGC-7901 cells. Cancer Biother. Radiopharm. 2013;28:146–152. PubMed

de Toledo M. Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One. 2012;7:e48344. PubMed PMC

An L. microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS One. 2013;8:e69478. PubMed PMC

Zhang L. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell. Signal. 2014;397:1–10. PubMed

Voorneveld P.W. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 2014;147:196–208. PubMed

Wang J. The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer. 2014;14:89. PubMed PMC

Wang Z.-M. ROCK inhibitor Y-27632 inhibits the growth, migration, and invasion of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma. Tumour Biol. 2016;37:3757–3764. PubMed

Salhia B. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005;65:8792–8800. PubMed

Matsuoka T. RhoA/ROCK signaling mediates plasticity of scirrhous gastric carcinoma motility. Clin. Exp. Metastasis. 2011;28:627–636. PubMed

Sadok A. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75:2272–2284. PubMed

Wei L. Novel insights into the roles of Rho kinase in cancer. Arch. Immunol. Ther. Exp. (Warsz) 2016;64:259–278. PubMed PMC

Ikenoya M. Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J. Neurochem. 2002;81:9–16. PubMed

Fagan-Solis K.D. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J. Cell. Biochem. 2013;114:1385–1394. PubMed

Nakajima M. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother. Pharmacol. 2003;52:319–324. PubMed

Loge C. Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885. J. Enzyme Inhib. Med. Chem. 2002;17:381–390. PubMed

Patel R.A. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012;72:5025–5034. PubMed PMC

Patel R.A. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene. 2014;33:550–555. PubMed PMC

Unbekandt M. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun. Signal. 2014;12:54. PubMed PMC

Kale V.P. A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion. Cancer Lett. 2014;4:1–12. PubMed PMC

Davies S.P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000;351:95–105. PubMed PMC

Feng Y. Rho kinase (ROCK) inhibitors and their therapeutic potential. J. Med. Chem. 2016;59:2269–2300. PubMed

Papadatos-Pastos D. A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. ASCO Annu. Meet. Proc. 2015;33:2566.

Schwab A., Stock C. Ion channels and transporters in tumour cell migration and invasion. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2014;369:20130102. PubMed PMC

The Lancet Oncology Cancer drug safety: time to re-focus on tackling adverse effects. Lancet Oncol. 2016;17:1463. PubMed

Steeg P.S. Targeting metastasis. Nat. Rev. Cancer. 2016;16:201–218. PubMed PMC

Scott V.R. New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species. Antimicrob. Agents Chemother. 1988;32:1154–1157. PubMed PMC

Hotulainen P., Hoogenraad C.C. Actin in dendritic spines: connecting dynamics to function. J. Cell Biol. 2010;189:619–629. PubMed PMC

Waschke J. Regulation of actin dynamics is critical for endothelial barrier functions. Am. J. Physiol. − Hear. Circ. Physiol. 2005;288:1296–1305. PubMed

Tashiro E., Imoto M. Screening and target identification of bioactive compounds that modulate cell migration and autophagy. Bioorg. Med. Chem. 2016;24:3283–3290. PubMed

Lyubchenko T.A. The actin cytoskeleton and cytotoxic T lymphocytes: evidence for multiple roles that could affect granule exocytosis-dependent target cell killing. J. Physiol. 2003;547:835–847. PubMed PMC

Zanin-Zhorov A. Isoform-specific targeting of ROCK proteins in immune cells. Small GTPases. 2016;7:173–177. PubMed PMC

Teiti I. In vivo effects in melanoma of ROCK inhibition-induced FasL overexpression. Front. Oncol. 2015;5:156. PubMed PMC

Kumper S. Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. eLife. 2016;5:e12994. PubMed PMC

Trendowski M. The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. Anticancer Res. 2014;34:2195–2202. PubMed

Trendowski M. The promise of sonodynamic therapy. Cancer Metastasis Rev. 2014;33:143–160. PubMed

Kolber M.A., Hill P. Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. Cancer Chemother. Pharmacol. 1992;30:286–290. PubMed

Somers K.D., Murphey M.M. Multinucleation in response to cytochalasin B: a common feature in several human tumor cell lines. Cancer Res. 1982;42:2575–2578. PubMed

Holzinger A. Jasplakinolide: An actin-specific reagent that promotes actin polymerization. Methods Mol. Biol. 2001;161:109–120. PubMed

Synthesis and migrastatic activity of cytochalasin analogues lacking a macrocyclic moiety

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer

Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging

The emerging role of microtubules in invasion plasticity

The Role of IL-6 in Cancer Cell Invasiveness and Metastasis-Overview and Therapeutic Opportunities

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

Are We Ready for Migrastatics?

Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model

Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19

Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review)

Sustained Inflammatory Signalling through Stat1/Stat2/IRF9 Is Associated with Amoeboid Phenotype of Melanoma Cells

High-throughput transcriptomic and proteomic profiling of mesenchymal-amoeboid transition in 3D collagen

Increased Level of Long Non-Coding RNA MALAT1 is a Common Feature of Amoeboid Invasion

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment

Solid cancer: the new tumour spread endpoint opens novel opportunities

Quantitative phase imaging unravels new insight into dynamics of mesenchymal and amoeboid cancer cell invasion

How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair

Distinctive behaviour of live biopsy-derived carcinoma cells unveiled using coherence-controlled holographic microscopy